• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Tolimidone

CAS No. 41964-07-2

Tolimidone ( MLR-1003 | MLR 1003 | MLR1003 | CID-39065 )

产品货号. M18535 CAS No. 41964-07-2

MLR-1023 是一种化合物,可抑制动物模型中的酸分泌,并且还可在组胺攻击的动物中充当支气管扩张剂。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
10MG ¥567 有现货
50MG ¥1539 有现货
100MG ¥2309 有现货
200MG 获取报价 有现货
500MG 获取报价 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    Tolimidone
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    MLR-1023 是一种化合物,可抑制动物模型中的酸分泌,并且还可在组胺攻击的动物中充当支气管扩张剂。
  • 产品描述
    MLR-1003 is a Lyn kinase activator that induces glycemic control.(In Vitro):Incubation of Tolimidone (MLR-1023) with Lyn kinase elicits a repeatable 50% increase in enzyme activity. Tolimidone elicits a concentration-dependent increase in Lyn kinase activation with a 2.3- and 2.1-fold increase achieved at concentrations of 3 and 10 μM, respectively. Inclusion of Tolimidone (100 μM) increases Lyn kinase activity by 3-fold at each ATP concentration tested (Vmax=2601 U/mg). Tolimidone-mediated activation of Lyn kinase increases in proportion to the length of preincubation period in the absence of ATP.(In Vivo):Administration of Tolimidone (MLR-1023) (30 mg/kg i.p.) significantly (p<0.05) lowers blood glucose levels to 148 and 158 mg/dL, 30 and 90 min after administration, respectively. Tolimidone significantly increases adipocyte differentiation and adiponectin production by 3.7- and 19-fold, respectively. Tolimidone elicits a dose-dependent potentiation of the insulin response, with a maximal effect observed with a dose level of 30 mg/kg.
  • 体外实验
    Incubation of Tolimidone (MLR-1023) with Lyn kinase elicits a repeatable 50% increase in enzyme activity. Tolimidone elicits a concentration-dependent increase in Lyn kinase activation with a 2.3- and 2.1-fold increase achieved at concentrations of 3 and 10 μM, respectively. Inclusion of Tolimidone (100 μM) increases Lyn kinase activity by 3-fold at each ATP concentration tested (Vmax=2601 U/mg). Tolimidone-mediated activation of Lyn kinase increases in proportion to the length of preincubation period in the absence of ATP.
  • 体内实验
    Administration of Tolimidone (MLR-1023) (30 mg/kg i.p.) significantly (p<0.05) lowers blood glucose levels to 148 and 158 mg/dL, 30 and 90 min after administration, respectively. Tolimidone significantly increases adipocyte differentiation and adiponectin production by 3.7- and 19-fold, respectively. Tolimidone elicits a dose-dependent potentiation of the insulin response, with a maximal effect observed with a dose level of 30 mg/kg.
  • 同义词
    MLR-1003 | MLR 1003 | MLR1003 | CID-39065
  • 通路
    Others
  • 靶点
    Other Targets
  • 受体
    Lyn kinase
  • 研究领域
    Others-Field
  • 适应症
    ——

化学信息

  • CAS Number
    41964-07-2
  • 分子量
    202.21
  • 分子式
    C11H10N2O2
  • 纯度
    >98% (HPLC)
  • 溶解度
    DMSO : 150 mg/mL 741.80 mM
  • SMILES
    CC1=CC=CC(OC2=CNC(=O)N=C2)=C1
  • 化学全称
    5-(3-Methylphenoxy)-2(1H)-pyrimidinone

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

产品手册
关联产品
  • DFHBI

    DFHBI 是一种小分子,类似于绿色荧光蛋白 (GFP) 的发色团。

  • GRP-60367

    GRP-60367是第一个小分子狂犬病病毒(RABV)进入抑制剂,对某些RABV毒株具有纳摩尔效应。Grp-60367抑制RABV毒株亚群的进入。Grp-60367表现出特异性和有效的抗RABV脚手架的活动。在剂量反应分析中,不同宿主细胞系的 EC50 范围为 2 至 52 nM。

  • BACE-IN-1

    BACE-IN-1 是淀粉样蛋白前体蛋白 β-分泌酶抑制剂。